NoNO begins Phase III trial of NA-1 to treat acute ischemic stroke

Canadian-based biotechnology company NoNO has begun the Phase III clinical trial (ESCAPE-NA-1) of NA-1 for the treatment of patients with acute ischemic stroke (AIS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news